Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05084508 · ClinicalTrials.gov registry record · Phase 2
A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 800
- Enrollment target
NCT05084508 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 800 participants.
The verdict
NCT05084508, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 800 participants
- Enrollment target
Study Summary
The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.
Interventions
- BIOLOGICAL Investigational varicella vaccine low potency
- BIOLOGICAL Investigational varicella vaccine medium potency
- BIOLOGICAL Investigational varicella vaccine high potency
- BIOLOGICAL Licensed varicella vaccine Lot 1
- BIOLOGICAL Licensed varicella vaccine Lot 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2022-02-03 |
| Est. Completion | 2024-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05084508
The ClinicalTrials.gov registry entry for NCT05084508 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Investigational varicella vaccine low potency is the first listed.
NCT05084508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05084508 about?
NCT05084508 is a clinical study titled "A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age". The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.
What is the current status of trial NCT05084508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 800 participants. The study started on 2022-02-03. Estimated completion is 2024-06-13.
What interventions are being tested in trial NCT05084508?
The interventions under investigation include: Investigational varicella vaccine low potency (BIOLOGICAL), Investigational varicella vaccine medium potency (BIOLOGICAL), Investigational varicella vaccine high potency (BIOLOGICAL), Licensed varicella vaccine Lot 1 (BIOLOGICAL), Licensed varicella vaccine Lot 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05084508?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.